Laminin-332 (Lm-332), a major basement membrane protein, has been shown to provide a niche for some stem cells. Here, we found that Lm-332 was expressed in osteoblasts, and is implicated in the regulation of osteoclast differentiation. Immunofluorescence analysis of laminin-β3, a unique component of Lm-332, indicated specific expression of laminin-β3 in osteoblast-like cells localized on bone surface. RT-PCR analysis confirmed that α3, β3, and γ2 chains of Lm-332 were all expressed in primary osteoblasts prepared from mouse calvaria. Lm-332 markedly inhibited osteoclastogenesis induced by receptor activator of nuclear factor kappa B (NF-κB) ligand (RANKL) when bone marrow-derived macrophages (BMMs) were cultured on Lm-332-coated plates. Lm-332 also blocked RANKL-induced activation of mitogen-activated protein kinases (MAPKs) (ERK, JNK, and p38) and expression of NFATc1, c-Fos, and c-Jun. Lm-332 suppressed osteoclast differentiation while retaining macrophage phenotypes, including nonspecific esterase activity and gene expression of lysozyme and EGF-like module-containing mucin-like hormone receptor-like 1 (Emr1). Furthermore, the treatment of primary osteoblasts with osteoclastogenic factors dramatically suppressed expression of Lm-332. These findings suggest that Lm-332 produced by osteoblasts in bone tissues has a pivotal role in controlling normal bone remodeling through suppressing osteoclastogenesis.
interfollicular epidermis, where it maintains hair follicle stem cells through the action of integrin-linked kinase (ILK), which is a key regulator of the bulge ECM microenvironments. 10 Lm-332 is also a component of the niche for human hepatic cancer stem cells 11 and for tumor cells in B-cell chronic lymphocytic leukemia. 12 Although the expression of Lm-332 has been observed in cultures of human mesenchymal stem cells 13 and bone marrow stromal cells, 14 it is unclear whether Lm-332 is expressed in bone tissues or bone marrow tissues in vivo.
Osteoclasts, multinuclear giant cells specialized in bone resorption, are derived from HSCs, and in normal osteoclastogenesis, differentiate from a common precursor of macrophages and osteoclasts. Their differentiation is basically supported by two essential cytokines, receptor activator of NF-κB ligand (RANKL), and macrophage colony-stimulating factor (M-CSF) [15] [16] [17] produced by cells in the osteoblast lineage. 18 Intracellular signaling after binding of RANKL to its receptor RANK has been extensively studied. In brief, TNF receptor-associated factor 6 (TRAF6) activates downstream signaling, including MAPK pathways, c-Jun-N-terminal kinase (JNK), and p38MAPK. Subsequently, this signaling activates transcription factors such as c-Fos and c-Jun, components of activator protein-1 (AP-1), 19, 20 and NFATc1, 21 which induce the expression of genes required for osteoclastogenesis. In addition to RANKL signaling, cell adhesion signaling through ECM proteins contributes to fine regulation of osteoclast differentiation. 22 Of the receptors for ECM proteins, integrins, composed of heterodimeric adhesion molecules with α and β subunits, have been extensively studied. Integrin αvβ3 expressed in osteoclasts recognizes the Arg-Gly-Asp (RGD) consensus sequence of ECM proteins, such as vitronectin and osteopontin, [22] [23] [24] which is thought to enable osteoclasts to bind bone surface and to perform bone resorption. Osteoclast precursors circulate throughout the vascular system. We have previously found that Lm-111, a component of the basement membrane of blood vessels, suppresses osteoclastogenesis. We have postulated that the differentiation of osteoclasts is negatively regulated by Lm-111 localized in the basement membrane of blood vessels present throughout the vascular system. 25 Here we investigated the expression of Lm-332 in bone tissues, and we examined the role of Lm-332 in the regulation of osteoclast differentiation. We found that Lm-332 is expressed in osteoblasts, and has an important regulatory role in osteoclastogenesis. Our findings suggest the presence of a novel mechanism operating through Lm-332 that controls normal bone remodeling.
MATERIALS AND METHODS Animals C57BL/6 mice were obtained from Kyudo (Tosu, Japan). Animal care and experiments were conducted in accordance with guidelines and procedures approved by the Institutional Animal Care and Use Committee of Kyushu University (protocol number: A27-179-0, A27-179-1).
Immunohistochemical Analysis
Femurs were excised from 5-to 6-week-old male C57BL/6 mice and immersed in 10% formalin neutral buffer solution for 24 h and demineralized in 10% (w/v) ethylene diamine tetraacetic acid disodium salt (EDTA-2Na; Dojindo) at room temperature for a week. The samples were dehydrated with graded ethanol and embedded in paraffin. For immunohistochemistry, the tissue sections of femurs were deparaffinized, rehydrated, and soaked in HistoVT One antigen retrieval solution (Nacalai, Kyoto, Japan). After blocking with Blocking One Histo (Nacalai), the sections were incubated with rabbit polyclonal antibody to laminin β3 (GeneTex, Irvine, CA, USA) at 4°C overnight in a humidified chamber, followed by three washes with TBS-Tween (TBST). The sections were further incubated with goat anti-rabbit IgG antibody conjugated with Alexa Fluor 488 (Molecular Probes, Eugene, OR, USA) and counterstained with DAPI for nuclei. The sections were mounted with Fluoromount/Plus (Diagnostic Biosystems, Pleasanton, CA, USA). Images were acquired on a Carl Zeiss fluorescent microscope using the Apotome function and ZEN software (Carl Zeiss, Jena, Germany).
Preparation and Culture of Osteoblasts
Primary osteoblasts were prepared from calvariae of 3-5-dayold C57BL/6 mice by five sequential digestions using 0.1% collagenase I (Wako Pure Chemicals). The cells were grown for 21 days in α-MEM containing 10% FBS in the presence of β-glycerophosphate and ascorbic acid (Wako Pure Chemicals). Alkaline phosphatase (ALP) activity was examined using TRAP/ALP Staining kit (Wako Pure Chemicals) according to the protocol provided in the kit. For 1,25(OH) 2 D 3 or PTH stimulation, primary osteoblasts were treated with 10 nM of 1,25(OH) 2 D 3 (Cayman, Ann Arbor, MI, USA) or 100 ng/ml of human PTH (1-31) (Bachem Bioscience, King of Prussia, PA, USA) as indicated in each experiment.
Immunofluorescence Analysis
Immunofluorescence analysis was performed as described previously. 26 Calvarial osteoblasts prepared from 3-to 5-dayold C57BL/6 mice were grown for 21 days on 35 mm glass bottom dishes (Matsunami Glass, Osaka, Japan) in α-MEM containing 10% FBS in the presence of β-glycerophosphate and ascorbic acid. After fixation with 10% formalin neutral buffer solution for 10 min, the cells were washed with TBST and blocked with Blocking One Histo (Nacalai) for 10 min. The cells were incubated with rabbit polyclonal antibody to laminin β3 overnight at 4°C. After washing with TBS, 0.1% Tween, cells were incubated with anti-rabbit IgG antibody conjugated with Alexa Fluor 488 (Molecular Probes) at room temperature for 1 h. The cells were then counterstained with DAPI for 5 min. Cells were imaged using BZ-8100 fluorescence microscope (Keyence). Non-immune Laminin-332 inhibits osteoclastogenesis N Uehara et al rabbit IgG (DAKO, Carpinteria, CA, USA) was used as the negative control in place of a primary antibody.
Cell Culture
Murine osteoclast precursor cell line, RAW264 D clone (RAW-D) 27, 28 was maintained in α-minimal essential medium (α-MEM) (Life Technologies, Carlsbad, CA, USA) containing 10% fetal bovine serum (FBS; Life Technologies) supplemented with 100 U/ml of penicillin and 100 mg/ml of streptomycin at 37°C in a 95% air/5% CO 2 atmosphere. The human recombinant Laminin-5 (Lm-332) was obtained from Oriental Yeast (Tokyo, Japan). The human Lm-511-E8 was obtained from Nippi (Tokyo, Japan). Culture plates were coated with each ECM protein overnight at 4°C and washed twice with PBS before use.
Preparation of BMMs and In Vitro Osteoclastogenesis
The femurs and tibiae were excised from 5-6-week-old male C57BL/6 mice. Bone marrow cells were cultured for 24 h in α-MEM containing 10% FBS in the presence of M-CSF (20 ng/ml). Non-adherent cells were collected and seeded in a 100 mm dish with α-MEM containing 10% FBS and 20 ng/ml M-CSF (Peprotech, London, UK). After 72 h, adherent cells were used as BMMs. For osteoclastogenesis, BMMs were further cultured in the presence of 20 ng/ml M-CSF and 50 ng/ml RANKL (Peprotech) for 4-5 days, and RAW-D cells were cultured in the presence of 50 ng/ml RANKL for 3 days. BMMs were plated onto 96-well plates and cultured in the presence of M-CSF and RANKL for up to 5 days. The cells were fixed and stained using the Acid Phosphatase, Leukocyte (TRAP) Kit (Sigma, Saint-Louis, MO, USA). The numbers of TRAP-positive multinuclear osteoclasts (with more than three nuclei) per well were counted.
Actin Ring Staining
BMMs were cultured in 96-well plates in the presence of M-CSF and RANKL for 4-5 days. The cells were then fixed with 10% formalin neutral buffer solution (WAKO, Osaka, Japan) and stained with fluorescein-labeled phalloidin (Life Technologies) for F-actin and with 4′,6-diamidino-2-phenylindole (DAPI; Dojindo Kumamoto, Japan) for nuclei. Images were captured using a BZ-8100 fluorescence microscope (Keyence, Osaka, Japan).
Quantitative Real-Time PCR Analysis
The mRNA expression was analyzed by quantitative real-time PCR with the Thermal Cycler Dice (TAKARA, Shiga, Japan). Total RNA was prepared using an RNeasy Mini kit (Qiagen, Valencia, CA, USA), and the cDNA was then reversetranscribed using a SuperScript III first-strand cDNA synthesis kit (Life Technologies). PCR amplification was performed in triplicate using a KAPA SYBR FAST qPCR kit (KAPA Biosystems, Boston, MA, USA). The PCR conditions were as follows: enzyme activation at 95°C for 30 s, 40 cycles of 5 s at 95°C and 20 s at 60°C. Expression was calculated using the comparative threshold cycle (CT) method. 29 Primer sequences used in this study are shown in Table 1 . 
Cell Proliferation Analysis

Western Blot Analysis
Western blots were performed as described previously. 30 Cell lysates were prepared by homogenization in cell lysis buffer (Cell Signaling Technology, Beverly, MA, USA) supplemented with protease inhibitor cocktail. Nuclear and cytoplasmic proteins were extracted by NE-PER nuclear and cytoplasmic extraction kit (Thermo Scientific, Rockford, lL, USA). The protein concentration of the supernatants was measured using a detergent-compatible protein assay kit (Bio-Rad). The following primary antibodies were used: anti-c-Jun, antiLamin A/C, anti-PARP-1, anti-Tubulin, anti-phospho-p44/42 
Laminin-332 inhibits osteoclastogenesis N Uehara et al MAPK (Thr202/Tyr204), anti-phospho-p38MAPK antibody (Thr180/Tyr182), anti-p38, anti-phospho-SAPK/JNK (Thr183/ Tyr185), and anti-SAPK/JNK, (Cell Signaling Technology); and anti-NFATc1, anti-c-Fos, anti-ERK1, and HRP-conjugated polyclonal anti-Actin antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Statistical Analysis
All discrete values are expressed as mean ± standard deviation (s.d.) from at least three independent experiments. The data were analyzed by paired t-test for comparison between two groups or by one-way analysis of variance (ANOVA) followed by the Tukey's test for multiple comparisons. Po0.05 was considered as statistically significant.
RESULTS
Expression of Lm-332 in Bone Tissues
As Lm-332 is the only laminim isoform that contains the β3 chain, we examined the localization of Lm-332 protein in bone tissues using an antibody specific for laminin β3 chain. Laminin β3 antibody selectively stained cuboidal osteoblastlike cells observed on surface of the bone in the metaphyseal area of the distal femur, but did not stain bone marrow ( Figure 1a , lower panels). Control IgG failed to stain any component of the bone (Figure 1a , upper panels). These data suggest that Lm-332 was expressed in cells in osteoblast lineage in bone tissues. To confirm the expression of Lm-332 in osteoblasts, expression of laminin α3, β3, and γ2 chains in primary osteoblasts was examined by immunostaining and PCR analysis. Calvarial-derived primary osteoblasts were Osteoblasts prepared from calvaria of newborn mice were cultured in 24-well plates in the presence of 2.5 mM β-glycerophosphate and 50 μg/ml ascorbic acid for 14 days to form mature osteoblasts. RT-PCR was used to amplify the indicated mRNA transcripts from mouse osteoblasts (14 days). The Runx2 and osteocalcin (Bglap) were used as a positive control for osteoblast maturation. β-actin (Actb) was amplified as a positive control. (c) The cells were fixed and stained for laminin-β3 and ALP as described in the 'Materials and Methods' section.
Laminin-332 inhibits osteoclastogenesis N Uehara et al cultured in the presence of β-glycerophosphate and ascorbic acid for 14 days to form mature osteoblasts, which secrete calcified matrices. PCR analysis of mature osteoblasts confirmed the expression of osteoblast markers including Runt-related transcription factor 2 (Runx2) and osteocalcin (Bglap). All three Lm-332 chain genes (laminin α3; Lama3, laminin β3; Lamb3, laminin γ2; Lamc2; Figure 1b ). Laminin β3 chain was detected in the cytoplasm of mature (ALPpositive) osteoblasts by immunofluorescence (Figure 1c ). These data indicate that Lm-332 is likely produced by osteoblasts in bone tissues. . In addition, osteoclastogenesis was inhibited by Lm-511-E8, a truncated laminin composed of the C-terminal regions of the α, β, and γ chains of Lm-511, and having the same affinity for integrin α6β1 as Lm-332 (Figure 2a and b) . We next examined the effect of Lm-332 on actin cytoskeleton organization. MNCs having typical actin rings were observed in control BMMs in response to RANKL; however, Lm-332 suppressed the formation of MNCs with actin rings (Figure 2c ). To further examine the inhibitory effect of Lm-332 on osteoclastogenesis, we investigated the expression of osteoclast marker genes, TRAP, Cathepsin K (Ctsk), ATPase, H+ transporting, lysosomal V0 subunit D2 (ATP6v0d2), Dendritic cell-specific transmembrane protein (Dcstamp), Integrin β3 (Itgb3), and Calcitonin receptor (Calcr). RANKL induced expression of osteoclast marker gene mRNA in BMMs cultured on Lm-332-non-coated culture plates (noncoated plates); whereas, coating plates with Lm-332 significantly suppressed the capacity of RANKL to induce expression of these genes (Figure 2d ). Lm-332 did not exhibit any cytotoxicity against BMMs and RAW-D cells, but rather slightly promoted proliferation of both BMMs and RAW-D cells (Figure 2e ), indicating that Lm-332 markedly suppressed osteoclastogenesis without diminishing cell viability.
Lm-332 Blocks Osteoclastogenesis in The Presence
Lm-332 Suppresses Induction and Nuclear Localization of AP-1 and NFATc1 in Response to RANKL
We next examined whether Lm-332 affected the expression in osteoclasts of two fundamental transcription factors downstream of RANKL signaling, AP-1 and NFATc1. Marked increases in Nfatc1 and c-fos mRNA levels were observed in BMMs cultured on non-coated plates 1 day after stimulation with RANKL; whereas, on Lm-332-coated plates their induction was suppressed in a dose-dependent manner (Figure 3a ). Induction and nuclear localization of NFATc1, c-Fos, and c-Jun proteins in response to RANKL was potently blocked by Lm-332 in BMMs (Figure 3b ).
Lm-332 Blocks RANKL-Induced Activation of MAPK Pathways RANKL stimulation triggers formation of a RANK-TRAF6 complex, which results in the activation of various downstream molecules, including MAPKs. 31 We next investigated whether Lm-332 affected MAPK signaling pathways in response to RANKL. BMMs were starved and then stimulated with RANKL. RANKL-induced phosphorylation of ERK, JNK, and p38MAPK was observed within 5 to 15 min in BMMs cultured on non-coated plates; whereas, the RANKLinduced phosphorylation of these MAPKs was markedly suppressed on Lm-332-coated plates (Figure 3c ). These data suggested that Lm-332 blocked early signaling events induced by RANKL, such as activation of MAPKs.
Lm-332 Attenuates Rank Expression and Retains a Macrophage Phenotype Even in the Presence of RANKL
Adhesion signaling mediated by α v β 3 integrin upregulates Rank expression, which is essential for RANKL-induced osteoclast differentiation. 32, 33 Laminins are also important transducers of adhesion signals through their receptors, including integrins, in many types of cells. We speculated that Lm-332 might affect Rank mRNA expression in osteoclast precursors. To determine this, the expression levels of Rank mRNA in BMMs and RAW-D cells were analyzed. We found that BMMs and RAW-D cells cultured on Laminin-332 inhibits osteoclastogenesis N Uehara et al non-coated plates exhibited a marked increase in Rank mRNA levels in response to RANKL, whereas Rank mRNA expression was significantly suppressed on Lm-332-coated plates in a dose-dependent manner (Figure 4a ). When BMMs were stimulated with RANKL under the non-coated condition, the expression level of Rank mRNA peaked at 2 days and remained high through day 4 ( Figure 4b ). However, BMMs cultured on Lm-332-coated plates failed to induce Rank mRNA in response to RANKL (Figure 4b ). To determine whether Lm-332 affected commitment to osteoclast differentiation in response to RANKL, we examined the macrophage markers nonspecific esterase (NSE) activity and expression of lysozyme (Lyz) and Emr1 ( Figure 5 ). When BMMs were cultured on non-coated plates, the proportion of NSE-positive cells was~80% before RANKL stimulation (day 0); the proportion of NSE-positive cells had significantly decreased (to~20%) by day 4 after treatment with RANKL, and was accompanied by formation of osteoclasts (Figure 5a , left panel). In contrast, BMMs cultured on Lm-332-coated plates retained NSE activity at day 4 as compared with BMMs before RANKL stimulation (day 0). BMMs cultured on noncoated plates stimulated with RANKL formed osteoclasts and exhibited decreased expression of macrophage marker genes, such as Lyz and Emr1. In contrast, on day 4, the expression of Lyz and Emr1 was not affected when BMMs were cultured on Lm-332-coated plates even in the presence of RANKL (Figure 5b ). These results suggested that Lm-332 selectively blocked osteoclastogenesis without affecting macrophage differentiation from bipotential precursors.
Osteoclastogenic Factors Suppress Lm-332 Expression in Osteoblasts RANKL expression is known to be induced by bone resorbing factors, such as 1α,25-dihydroxyvitamin D 3 (1,25(OH) 2 D 3 ) or parathyroid hormone (PTH). 34, 35 In light of the inhibitory effect of Lm-332 on osteoclastogenesis and the expression of Lm-332 in osteoblasts, we analyzed expression of three components of Lm-332 in osteoblasts after treatment with 1,25(OH) 2 D 3 or PTH. Expression of all three laminin-332 chains (Lama3, Lamb3, and Lamc2) was markedly suppressed after treatment of osteoblasts with 1,25(OH) 2 D 3 ( Figure 6a) . Similarly, the expression of all three laminin-332 chains (Lama3, Lamb3, and Lamc2) was also suppressed by PTH treatment (Figure 6b ). These data indicated that the osteoclastogenic factors that act by inducing RANKL expression efficiently suppressed production of Lm-332, a key negative regulator of osteoclast differentiation.
DISCUSSION
We provide evidence that laminin β3, a specific chain of Lm-332, is present in osteoblast-like cells localized on the bone surface. In our in vitro studies, we confirmed that Lm-332 was expressed in primary osteoblasts. We also obtained lines of evidence indicating that Lm-332 had the ability to suppress osteoclastogenesis. In normal osteoclastogenesis, osteoclasts are formed on bone surface. Lm-332 produced from osteoblasts is thought to contribute to a fine modulation of osteoclastogenesis in normal bone remodeling.
We have clarified that both Lm-332 and Lm-511-E8 exert an inhibitory effect on osteoclastogenesis. Among the subunits of laminin, the C-terminal of laminin α chain is utilized for binding to integrins. 5 Lm-332 preferentially binds to integrin α3β1 and/or α6β1, and proteolytically processed α3 laminin G (LG) domains bind to integrin α6β4. 36 Lm-511-E8 is a truncated protein composed of the C-terminal regions of the α, β, and γ chains of Lm-511 that retain the full capability and high affinity for binding to integrin α6β1. 37, 38 Suppression of osteoclastogenesis induced by Lm-332 or Lm-511 is thought to be mediated through integrin α6β1. We have confirmed the expression of integrin α6 and β1 in BMMs (data not shown).
Lm-332 blocked RANKL-induced phosphorylation of MAPKs (ERK, JNK, and p38) in BMMs as the early event.
Lm-332 suppressed RANKL-induced expression of NFATc1 and c-fos and blocked nuclear localization of these transcription factors. These events are considered to be the main mechanism for inhibition of osteoclastogenesis. It will be of interest to elucidate the types of intracellular signaling that follow binding of Lm-332 to the receptor expressed on In contrast, RAW-D is an osteoclast precursor cell line that was established from one cell that was highly responsive to RANKL-stimuli. As RAW-D cells at baseline express high levels of Rank mRNA, 28 it is reasonable that the Rank mRNA level upregulated only twofold in response to RANKL. It will be important to determine whether upregulaton of Rank mRNA expression by RANKL is suppressed by Lm-332 by use of the reporter assay system using Rank promoter. It has been proposed that there are two types of bone marrow niches for HSC maintenance: the endosteal niche, populated by osteoblasts, and the vascular niche, which includes sinusoids and endothelial cells. 1 Osteoclasts are derived from HSCs, and their differentiation is supported by bone marrow stromal cells or osteoblasts through cell-cell interactions. 18 In the current study, immunohistochemical analysis for laminin β3 indicated that the fluorescence signal was detected in cells lining limited areas of the bone surface, indicating that Lm-332 is possibly expressed in a subset of cells in the osteoblast lineage. We have confirmed the expression of all chains of Lm-332 in primary osteoblasts by use of RT-PCR and immunofluorescence staining. 
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Osteoblasts secrete proteins such as OPG and Semaphorin 3A, both of which exert osteoprotective effects by suppressing osteoclast differentiation and function. 39 Osteoclast differentiation is induced by RANKL, which is expressed by osteoblasts and bone marrow stromal cells in response to osteotropic factors such as 1,25(OH) 2 D 3 , prostagrandin E2 or PTH. All three components of Lm-332 were detected in primary osteoblasts, but their expression was markedly suppressed by treatment with osteoclastogenic factors that induce RANKL, such as 1,25(OH) 2 D 3 and PTH. As illustrated in our model shown in Figure 6c , the interplay of these factors determines the formation or inhibition of osteoclasts (Figure 6c ). Our findings suggest that Lm-332 is a novel osteoprotective factor produced by osteoblasts.
The results presented here provide novel evidence indicating that Lm-332 exerts inhibitory effects on RANKL-induced osteoclastogenesis. This effect was accompanied by inhibition of induction of Rank mRNA expression and retention of Figure 6 Suppression of Lm-332 expression by treatment with osteoclastogenic factors. Osteoblasts prepared from calvaria of newborn mice were treated with 10 nM of 1α,25-dihydroxyvitamin D 3 (a) or 100 ng/ml of PTH (b) for 7 days. mRNA expression of laminin-α3 (Lama3), -β3 (Lamb3), and -γ2 (Lamc2) was analyzed by quantitative real-time PCR. For each target gene, the expression was normalized to Actb, and the expression level is shown relative to the control of day 0 culture (designated as 1) for comparison; bars, ± s.d. **Po0.01 by paired t-test. (c) Hypothetical model of the role of Lm-332 in modulation of osteoclastogenesis. In the absence of osteoclastogenic factors, Lm-332 secreted by osteoblasts suppresses osteoclastogenesis and supports the maintenance of the macrophage population. In the presence of osteoclastogenic factors such as 1α,25-dihydroxyvitamin D 3 or PTH, Lm-332 production in osteoblasts is markedly suppressed, which allows promotion of osteoclastogenesis through RANK/RANKL signaling. MΦ, macrophage.
Laminin-332 inhibits osteoclastogenesis N Uehara et al macrophage phenotypes by BMMs. In addition, Lm-332 was expressed by primary osteoblasts in culture, and its expression was negatively regulated by osteoclastogenic factors, suggesting that Lm-332 is a novel negative regulator that may define osteoclastogenesis spatiotemporally in bone tissues. It will be important to elucidate the molecular mechanisms by which adhesion signaling via Lm-332 regulates osteoclastogenesis. Insights from our findings may contribute to the development of strategies for the fine regulation of bone metabolism.
